


VISCHER ADVISED VERSAMEB IN ITS CHF 6 MILLION SEED FINANCING ROUND

Posted on 22 July 2020



Category: [Deal & transactions](#)

Tags: [Dania Salvisberg-Schneider](#), [Matthias Staehelin](#), [Moritz Jäggy](#), [Slider](#), [Versameb](#), [Vischer](#)



Versameb, a preclinical-stage biopharmaceutical company located in Basel, has closed a CHF 6 million seed financing round. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform developing molecules targeting regulation of immune response or regeneration in the fields of dermatology, oncology and myology.

The advisor

VISCHER [advises Versameb in this transaction](#). The team included partner **Matthias Staehelin (pictured)**, managing associates **Moritz Jäggy** and **Dania Salvisberg-Schneider (all Corporate)**.